Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 537 - 544 of 12089 results
Best Practices in Developing Winning IP Strategies for AI Companies
November 14, 2024| Article| Viewpoint
Insurance Industry Key in Net-Zero Transition, UN Group Says
November 14, 2024| News
Fertility Related Loss To Be Covered Under the Massachusetts Earned Sick Time Act
November 13, 2024| Blog| Viewpoint
Trump EPA Pick Seen Supporting PFAS Limits, Revising Water Rules
November 13, 2024| News
First CRISPR-Cas9 Drug Monetised in Spate of Big-Money Royalty Transactions
November 12, 2024| News
Trump's Selection of Zeldin to Head EPA Draws Surprise, Little Hope of Avoiding Deregulation
November 12, 2024| News
The Federal Circuit Swings the Door to Anti-Suit Injunctions Back Open
November 8, 2024| Blog| Viewpoint
Can a beneficiary serve as a witness in a will contest without losing their inheritance? The Massachusetts Appeals Court says yes.
November 8, 2024| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|